Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315

Episode Summary

Executive Summary: Live from Tokyo for Founder University Japan, Jason and longevity startup Eki Labs’ Bilal Karoni discuss epigenetic data generation, AI in biotech, Japan’s pro-regenerative-medicine ecosystem, and hard founder choices like focus, cap tables, hiring, and exit timing. The conversation also explores longevity ethics, right-to-try, blue zones, and how companies should balance hustle with sustainable health.

Main Topics: Eki Labs’ longevity-data business (Priority: 5/5): Bilal explains that Eki Labs generates high-resolution, low-cost epigenetic data for drug development and cell-therapy quality control, positioning data generation as its core moat in longevity research. Japan as a biotech and longevity hub (Priority: 5/5): The discussion highlights Japan’s aging population, strong research base, regenerative-medicine regulation, and Okinawa/OIST as reasons Eki Labs chose to build there. AI in biology and data generation as the bottleneck (Priority: 5/5): Bilal argues that biology AI is constrained by insufficient, phenotype-specific data, so the company focuses on generating proprietary datasets rather than relying on public data alone. Founder decision-making: focus, product-market fit, and exits (Priority: 4/5): The pair discuss pruning revenue-generating but distracting services, building platform value, and how founders should think about acquisition timing and unreasonable offers. Longevity ethics, stem cells, and right to try (Priority: 4/5): They debate off-label longevity interventions, clinical indications, patient autonomy, and the moral limits of advancing science by exposing healthy people to disease. Culture, workload, and sustainable performance (Priority: 3/5): A live audience Q&A covers 996-style hustle, sleep, burnout, and whether longevity companies should optimize employee health and working patterns. Blue zones, social connection, and biological age (Priority: 3/5): The conversation covers the controversy around blue-zone data, the role of social support in longevity, and how biological age biomarkers should be used more for trends and trials than consumer self-optimization.

Key Arguments: Eki Labs’ moat is not AI models themselves but the generation of novel epigenetic data that public datasets do not provide. Longevity science needs clinical validation; many current wellness or off-menu interventions lack consensus and should be judged by indication, efficacy, and safety. Japan offers a unique combination of high-quality science, regenerative-medicine regulation, and a large aging population, making it strategically attractive for longevity biotech. Founders should cut distraction even if a side business generates revenue when it does not compound into long-term platform value. In biotech, small Japanese checks can still be powerful because lower operating costs and non-dilutive funding sources extend runway and preserve cap table cleanliness. Right-to-try is compelling for terminally ill patients, but deliberately infecting healthy people for research crosses an ethical line for the guest. Biological-age metrics are most useful as cohort benchmarks and trend signals, not as consumer gamification targets. Longevity and productivity depend on sustainability: hard work is necessary, but chronic sleep deprivation and burnout undermine performance. Social connection, routine, and supportive networks are important mechanisms behind blue-zone longevity claims.

Data Points: Founder University cohort size: about 40 founders in the room - Jason notes the Tokyo live audience and says the discussion is with roughly forty founders. Founder University scale: thousands of applications per year - Jason describes demand for the pre-accelerator program. Founder University capacity: a couple of hundred spots - Jason explains the program admits only a limited number of founders. Founder University duration: 12 weeks - Jason explains the length of the program. Geographic footprint: 3 continents - Founder University is run in Japan, Saudi Arabia, and the U.S./internationally. Eki Labs operating history: 3–4 years - Jason says the company has been building and is already in market. Customer cohorts: hundreds and sometimes thousands of participants - Bilal describes the scale of studies Eki Labs serves. Funding raised: $1 million seed funding plus grants - Jason references the company’s financing structure in Japan. Angel check sizes: $5K to $200K - Bilal discusses typical Japanese angel-investor ticket sizes. IPO revenue threshold (historic): as little as $5M–$10M in revenue - Jason discusses the former Japanese IPO environment before regulatory changes. Sleep claim in Q&A: 0 to 3 hours a night - Bilal cites a Prime Minister’s reported sleep schedule as unsustainable. AI drug milestone: first AI-designed drug reached phase 3 - Bilal says this shows the field is advancing toward regulated therapeutics.

Pivotal Quotes: "We generate high-resolution and low-cost epigenetic data for drug development." — Bilal Karoni: Bilal’s concise description of Eki Labs’ core product and business model. "In AI for biology, the moat is in data generation." — Bilal Karoni: He explains why his company prioritizes novel datasets over generic modeling. "Great companies are bought, not sold." — Jason Calacanis: Jason gives exit advice during the live founder Q&A, emphasizing leverage and multiple bidders.

Implications: The episode shows where longevity biotech is heading: proprietary biological data, not hype, will determine winners. For founders, focus and capital efficiency matter as much as science. For the industry, Japan’s regulatory and research environment may become a major global advantage.